Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare
- PDF / 1,889,143 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 10 Downloads / 168 Views
ORIGINAL RESEARCH
Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals Georg M. N. Behrens . Anne Cossmann . Metodi V. Stankov . ¨ rster . Berislav Bosnjak . Bianca Schulte . Hendrik Streeck . Reinhold Fo Stefanie Willenzon . Anna-Lena Boeck . Anh Thu Tran . Thea Thiele . Theresa Graalmann . Moritz Z. Kayser . Anna Zychlinsky Scharff . Christian Dopfer . Alexander Horke . Isabell Pink . Torsten Witte . Martin Wetzke . Diana Ernst . Alexandra Jablonka
.
Christine Happle Received: July 31, 2020 Ó The Author(s) 2020
ABSTRACT Background: Serology testing is explored for epidemiological research and to inform
Georg M. N. Behrens, Anne Cossmann, Alexandra Jablonka and Christine Happle contributed equally to this work.
Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12841166. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40121020-00334-1) contains supplementary material, which is available to authorized users.
individuals after suspected infection. During the coronavirus disease 2019 (COVID-19) pandemic, frontline healthcare professionals (HCP) may be at particular risk for infection. No longitudinal data on functional seroconversion in HCP in regions with low COVID-19 prevalence and low pre-test probability exist. Methods: In a large German university hospital, we performed weekly questionnaire assessments and anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) measurements with various commercial tests, a novel surrogate virus neutralisation test, and a neutralisation assay using live SARS-CoV-2.
G. M. N. Behrens (&) A. Cossmann M. V. Stankov T. Thiele T. Graalmann T. Witte D. Ernst A. Jablonka Department for Rheumatology and Clinical Immunology, Hannover Medical School, Hannover, Germany e-mail: [email protected]
B. Schulte H. Streeck Institute of Virology, University Hospital, University of Bonn, Bonn, Germany
G. M. N. Behrens A. Cossmann M. V. Stankov M. Wetzke A. Jablonka German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Brunswick, Germany
¨ rster B. Bosnjak S. Willenzon R. Fo Institute for Immunology, Hannover Medical School, Hannover, Germany
G. M. N. Behrens CiiM, Centre for Individualised Infection Medicine, Hannover, Germany
B. Schulte H. Streeck German Center for Infection Research (DZIF), ¨ ln, Bonn, Germany Partner Site Bonn-Ko
¨ rster R. Fo Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany
Infect Dis Ther
Results: From baseline to week 6, 1080 screening measurements for anti-SARS CoV-2 (S1) IgG from 217 frontline HCP (65% female) were performed. Overall, 75.6% of HCP reported at least one symptom of respiratory infection. Self-perceived infection probability declined over time (from mean 20.1% at baseline to 12.4% in week 6, p \ 0.001). In sera of convalescent patients w
Data Loading...
